Tff Pharmaceuticals Inc
TFF Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing (TFF) technology platform in the United States and Australia. It intends to focus on the development of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions. The company's drug candidates are TFF Voricona… Read more
Tff Pharmaceuticals Inc (TFFP) - Total Liabilities
Latest total liabilities as of September 2024: $3.94 Million USD
Based on the latest financial reports, Tff Pharmaceuticals Inc (TFFP) has total liabilities worth $3.94 Million USD as of September 2024.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Tff Pharmaceuticals Inc - Total Liabilities Trend (2016–2023)
This chart illustrates how Tff Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Tff Pharmaceuticals Inc Competitors by Total Liabilities
The table below lists competitors of Tff Pharmaceuticals Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
BBVA - Dusseldorf Stock Exchang
DU:BOY
|
Germany | €712.57 Billion |
|
FISH & PAYK HEALTH
BE:FPLB
|
Germany | €522.60 Million |
|
Cohen & Steers Tax-Advantaged Preferred Securities and Income Fund
NYSE:PTA
|
USA | $610.54 Million |
|
ALTCF
PINK:ALTCF
|
USA | $2.28 Million |
|
Grayscale Decentralized Finance (DeFi) Fund LLC
OTCQB:DEFG
|
USA | $0.00 |
|
Qwest Corp. NT
NYSE:CTBB
|
USA | $33.65 Billion |
|
Electrica SA
LSE:ELSA
|
UK | £8.04 Billion |
Liability Composition Analysis (2016–2023)
This chart breaks down Tff Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.89 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.26 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.56 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Tff Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Tff Pharmaceuticals Inc (2016–2023)
The table below shows the annual total liabilities of Tff Pharmaceuticals Inc from 2016 to 2023.
| Year | Total Liabilities | Change |
|---|---|---|
| 2023-12-31 | $2.46 Million | +98.29% |
| 2022-12-31 | $1.24 Million | -36.72% |
| 2021-12-31 | $1.96 Million | +48.31% |
| 2020-12-31 | $1.32 Million | -14.30% |
| 2019-12-31 | $1.54 Million | +33.33% |
| 2018-12-31 | $1.16 Million | +63020.29% |
| 2017-12-31 | $1.83K | -83.30% |
| 2016-12-31 | $10.98K | -- |